PlayBall10

ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial ResultsAdditional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential ne...

www.proqr.com/press-releases/proqr-an...ProQR Announces First Quarter 2021 Operating and Financial Results- Phase 2/3 pivotal Illum...

Nog een podcast, nu met de CEO: globalgenes.org/rare-cast/episode-309/ ...

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)ir.proqr.com/news-releases/news-relea...

[quote alias=Mj25 id=12198526 date=202003101905]Mensen even een vraag, waar kan ik de openingskoersen van de aandelen n de indexen vinden? Ik heb me al suf gegoogeled en bij binck gekeken maar...

ProQR (PRQR) Receives a Buy from H.C. Wainwrightwww.smarteranalyst.com/brief/proqr-pr...

ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticalsir.proqr.com/news-releases/news-relea...

ProQr boekt vooruitgang met medicijn tegen zeldzame blindheidHet Nederlandse biotechbedrijf ProQr PRQR$12,55+57,86% heeft mogelijk een medicijn ontwikkeld tegen LCA10, een zeldzame ziekte die blindh...

First Human Trial to Evaluate QR-313 for Dystrophic Epidermolysis Bullosa Initiatedwww.raredr.com/news/first-human-trial...

ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference4 June 2018 at 7:00 AM EDTLEIDEN, The Netherlands, June 04, 2018 (GLOBE...

Daniel de Boer, Founder and CEO of ProQR, discusses Leber’s congenital amaurosis (LCA), the most common genetic cause of childhood blindness that affects about 15,000 patients in the Western world. ...

Aescap 2.0 passed 5% threshold in biotech ProQRYesterday evening Aescap 2.0 filed with the SEC that it has crossed the 5% shareholding threshold and currently owns 5.6% of the Nasdaq listed Dutch ...

Helaas. Het laatste wat ik van Leerink heb is van 14 februari....

ir.proqr.com/static-files/6a5fbdf0-1f...ProQRs Annual Magazine 2017We started ProQR Therapeutics five years ago to find a treatment for cystic fibrosis. Since...

Galapagos, Editas, Ionis und ProQR jagen Vertex im Kampf um den Milliardenmarkt Mukoviszidosewww.fool.de/2018/03/14/galapagos-edit...

labiotech.eu/proqr-cystic-fibrosis-da...

Mooie wetenschappelijke publicatie over Fuchs, een van de oog indicaties van ProQr ...

Nieuwe analist: Opus National Capital Markets.ProQR Therapeutics N.V. (PRQR): Leveraging its Expertise in mRNA Correction – Many Shots on Goal Given the Numerous Treatable Diseases: Initiating BUY/$...

30th Annual ROTH ConferenceOn Monday, March 12, 2018 at 12:00 pm PT, Smital Shah, Chief Financial Officer of ProQR, will present at the 30th Annual Roth Conference. The conference is being held at ...

Wainwright: ProQR Pivots in 2018 to Focus on Ophthalmology Opportunities. Rating: Buy; Price Target: $40.00...

JMP: In-Line Financials as PRQR Pushes Rare Disease Pipeline into the Clinic...

Leerink: 4Q Recap: All Eyes Set on Pompe/Fabry Updates in 2Q/3Q; PT to $22 / Outperform...

twitter.com/MorphoSys www.aad.org/scientificsessions/am2018...

Nogmaals Leerink...

Nu in pdf (gisteren meerdere keren geprobeerd)...

JMP...

Leerink...

labiotech.eu/galapagos-proqr-fibrosis...

Leerink 8 januari 2018...

www.biocentury.com/bc-extra/company-n...

ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer technology8 January 2018 at 7:00 AM ESTLEIDEN, the Netherlands, Jan. 08, 2018 (G...

ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa Key Updates•ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullo...

Leerink:• Bottom Line: Today PRQR announced dosing of the first patientin its ph.1/2 program for QR-110 in Leber’s congenital amaurosis10 (LCA 10), a rare genetic disorder resulting in blindness...

ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness Key Updates•The first patient has received the first dose of QR-110 in the Phase 1/...

ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board Dr. Thaddeus (Ted) Dryja, a pioneer in the field of retinal genetic diseases, joins the Company’s Scientific Advisory Board.Dr. ...

cysticfibrosisnewstoday.com/2017/11/0...

JPG...

De analisten blijven positief. Wainwright....

Deel 4 en slot...

Onno van de Stolpe in Effect (VEB): Ik denk overigens dat we de komende jaren wat betreft organisatie en resultaat en dus beurswaarde zo snel kunnen groeien dat het lastiger wordt voor Gilead om te ov...

Deel 2...

Deel 3...

ProQR to Present at the Chardan Inaugural Gene Therapy ConferenceLEIDEN, the Netherlands, Oct. 06, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing liv...

ProQR’s Inhaled RNA Therapy Improves CF Symptoms in Phase 1 Clinical Trialcysticfibrosisnewstoday.com/2017/09/2...

En tot slot Wainwright...

Dank ivet voor het plaatsen van de rapporten. Hierbij de volledige versie van Leerink...

JMP...

JMP - koersdoel $14...

ProQR to Present at Two Investor Conferences in SeptemberLEIDEN, the Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will prese...

ProQR Presents in vivo Proof of Concept Data for the Axiomer RNA Editing Platform TechnologyKey updatesProQR presents in vivo data in a relevant disease model, establishing proof of concep...